These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1128 related items for PubMed ID: 25765966
1. Immunogenicity and safety of a combined measles, mumps, rubella and varicella live vaccine (ProQuad ®) administered concomitantly with a booster dose of a hexavalent vaccine in 12-23-month-old infants. Deichmann KA, Ferrera G, Tran C, Thomas S, Eymin C, Baudin M. Vaccine; 2015 May 11; 33(20):2379-86. PubMed ID: 25765966 [Abstract] [Full Text] [Related]
3. Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines. Shinefield H, Black S, Thear M, Coury D, Reisinger K, Rothstein E, Xu J, Hartzel J, Evans B, Digilio L, Schödel F, Brown ML, Kuter B, 013 Study Group for ProQuad. Pediatr Infect Dis J; 2006 Apr 11; 25(4):287-92. PubMed ID: 16567978 [Abstract] [Full Text] [Related]
9. Investigation of an increase in large local reactions following vaccine schedule change to include DTaP-HB-IPV-Hib (Infanrix-hexa®) and MMRV (ProQuad®) at 18 months of age. Kiely M, Billard MN, Toth E, Zafack JG, Landry M, Skowronski DM, De Serres G. Vaccine; 2018 Oct 29; 36(45):6688-6694. PubMed ID: 30269915 [Abstract] [Full Text] [Related]
11. Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib). Martinón-Torres F, Boisnard F, Thomas S, Sadorge C, Borrow R, PRI02C study group. Vaccine; 2017 Jun 27; 35(30):3764-3772. PubMed ID: 28583305 [Abstract] [Full Text] [Related]
13. Concomitant administration of a fully liquid, ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal serogroup C conjugate vaccine in infants. Vesikari T, Borrow R, Da Costa X, Richard P, Eymin C, Boisnard F, Lockhart S. Vaccine; 2017 Jan 11; 35(3):452-458. PubMed ID: 27939054 [Abstract] [Full Text] [Related]
14. Immunization of preterm infants with GSK's hexavalent combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine: A review of safety and immunogenicity. Omeñaca F, Vázquez L, Garcia-Corbeira P, Mesaros N, Hanssens L, Dolhain J, Gómez IP, Liese J, Knuf M. Vaccine; 2018 Feb 08; 36(7):986-996. PubMed ID: 29336924 [Abstract] [Full Text] [Related]
15. Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age. Arístegui J, Dal-Ré R, Díez-Delgado J, Marés J, Casanovas JM, García-Corbeira P, De Frutos E, Van Esso D, Verdaguer J, De la Flor J, Moraga F, Boceta R, García-Martínez JA. Vaccine; 2003 Sep 08; 21(25-26):3593-600. PubMed ID: 12922087 [Abstract] [Full Text] [Related]
16. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants. Lagos R, Kotloff K, Hoffenbach A, San Martin O, Abrego P, Ureta AM, Pines E, Blondeau C, Bailleux F, Levine MM. Pediatr Infect Dis J; 1998 Apr 08; 17(4):294-304. PubMed ID: 9576383 [Abstract] [Full Text] [Related]